تداخلات دوتاستيريد

Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2) ]. (نشرة دوتاستيريد، موانع الاستعمال)

Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2) ]. (نشرة دوتاستيريد، موانع الاستعمال)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Dutasteride Oxybutynin Sildenafil (for erectile dysfunction) Tadalafil (for erectile dysfunction and benign prostatic hyperplasia) Tolterodine Monitor for adverse reactions. (نشرة إيتراكونازول، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Digoxin Dutasteride capsules do not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks [see Clinical Pharmacology (12.3) ]. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). (نشرة دوتاستيريد، التداخلات الدوائية)

Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

Coadministration of dutasteride and tamsulosin resulted in similar changes to serum PSA as dutasteride monotherapy. (نشرة دوتاستيريد، التحذيرات والاحتياطات)

The effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters has not been evaluated. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (نشرة دوتاستيريد، التداخلات الدوائية)

Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (نشرة دوتاستيريد، التداخلات الدوائية)

Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (نشرة دوتاستيريد، التداخلات الدوائية)

Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (نشرة دوتاستيريد، التداخلات الدوائية)

Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (نشرة دوتاستيريد، التداخلات الدوائية)

Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (نشرة دوتاستيريد، التداخلات الدوائية)

Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (نشرة دوتاستيريد، التداخلات الدوائية)

Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (نشرة دوتاستيريد، التداخلات الدوائية)

Cholestyramine Administration of a single 5-mg dose of dutasteride capsules followed 1 hour later by 12 g of cholestyramine does not affect the relative bioavailability of dutasteride [see Clinical Pharmacology (12.3) ]. (نشرة دوتاستيريد، التداخلات الدوائية)

Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (نشرة دوتاستيريد، التداخلات الدوائية)

Warfarin Concomitant administration of dutasteride capsules 0.5 mg/day for 3 weeks with warfarin does not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time [see Clinical Pharmacology (12.3) ]. (نشرة دوتاستيريد، التداخلات الدوائية)